CD274 and neoplasm: Recent preclinical data have shown that intratumoral injections of tozinameran induce abundant tumor-infiltrating lymphocytes with enhanced local levels of proinflammatory markers and significantly increased expression of PD-L1 on tumor-associated immune cells.